Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C

Regentis Biomaterials (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage that could help address the substantial clinical and economic burden associated with knee osteoarthritis (“OA”). Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies. With approximately 470,000 knee cartilage repair procedures performed annually in the U.S., representing an estimated $3 billion market, the company believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The article highlights estimates that the annual U.S. economic burden of knee OA ranges from approximately $5.7 billion to $15 billion, with lifetime costs for affected patients potentially exceeding $140,000. As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease.

At a glance

Company: Regentis Biomaterials Ltd.
Ticker: NYSE American: RGNT
Announcement: Product

Key figures

Annual U.S. knee cartilage repair procedures: approximately 470,000
Estimated U.S. knee cartilage repair market: $3 billion
Estimated annual U.S. knee OA economic burden: approximately $5.7 billion to $15 billion
Potential lifetime costs for affected patients: exceeding $140,000
Gelrin C procedure duration: 10-minute

Products and programs

Gelrin C
Gelrin platform technology

To view the full article, visit https://ibn.fm/yPKU2

About Regentis Biomaterials Ltd.

Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore health and enhance quality of life. With an initial focus on orthopedic treatments, Regentis’ Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone. Regentis’ lead product GelrinC(R) is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing the surrounding cells to regenerate the cartilage in a controlled and synchronous process. GelrinC(R) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available.

This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Corporate Communications

IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]

In brief

Regentis Biomaterials says its cell-free Gelrin C hydrogel could provide an alternative approach to knee cartilage repair. The product is designed for a single 10-minute procedure and is intended to support cartilage regeneration without cell-based therapies’ laboratory processing, according to the company. The release cites approximately 470,000 knee cartilage repair procedures performed annually in the United States and an estimated $3 billion market. It also points to estimates that knee osteoarthritis carries an annual U.S. economic burden of approximately $5.7 billion to $15 billion, with affected patients’ lifetime costs potentially above $140,000. Regentis is advancing Gelrin C toward commercialization and says its design is intended to fit existing surgical workflows. The release describes the material as resorbed in the knee while surrounding cells regenerate cartilage.

Key takeaways

Regentis says Gelrin C is a cell-free hydrogel designed for a single 10-minute knee procedure.
The release cites approximately 470,000 U.S. knee cartilage repair procedures each year and an estimated $3 billion market.
It reports estimates of $5.7 billion to $15 billion in annual U.S. knee osteoarthritis costs.
The company says it is advancing Gelrin C toward commercialization.

SEC filings

Earlier from Regentis Biomaterials Ltd.

Back to News Center